Open an account

Cellectis SA

CLLS · NYSE

$0.98+$0.005 (+0.51%)TodayMarket closed ·
Prev close $0.975

About CLLS

Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company is headquartered in Paris, Ile-De-France and currently employs 229 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.

Employees
229
Headquarters
Paris, Ile-De-France
Listed
Feb 6, 2007
Sector
Health Care
Industry
Biotechnology
Website
cellectis.com

CLLS key statistics

Market cap
68.46M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
106.47K
Volume
13.63K
Open price
$1.00
High today
$1.02
Low today
$0.959
52 Week high
$5.45
52 Week low
$0.8808

Cellectis SA (CLLS) at a glance

As of Oct 23, 2026, Cellectis SA (CLLS) shares are priced at $0.98, giving the company a market cap of 68.46M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.959 and $1.02. The current price is 2.2% above the day's low and 3.7% below its high.

Volume so far is 13.63K shares, below the average of 106.47K shares a day.

Over the past year Cellectis SA has ranged from $0.8808 to $5.45, and now sits 2% of the way up that range.

Cellectis SA met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported -$0.22 per share against an estimate of -$0.2781.

The average analyst price target is $3.18, 224.2% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

40%of 5 analyst ratings say Buy
  • Buy40.0%
  • Hold40.0%
  • Sell20.0%
Price target · 3 analystsAvg $3.18
Low
$3.15
Now
$0.98
High
$3.27

CLLS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 44.5% on average.

  1. Q3 FY24: reported -$0.23 per share against an estimate of -$0.2815
  2. Q4 FY24: reported $0.08 per share against an estimate of -$0.1751
  3. Q1 FY25: reported -$0.18 per share against an estimate of -$0.2415
  4. Q2 FY25: reported -$0.24 per share against an estimate of -$0.251
  5. Q3 FY25: reported $0.01 per share against an estimate of -$0.2858
  6. Q4 FY25: reported -$0.26 per share against an estimate of -$0.2647
  7. Q1 FY26: reported -$0.18 per share against an estimate of -$0.2814
  8. Q2 FY26: reported -$0.22 per share against an estimate of -$0.2781

CLLS news

  • Press releaseGlobe Newswire

    Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS

  • Press releaseGlobe Newswire

    Cellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

  • Press releaseGlobe Newswire

    Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.